Faithward Advisors LLC Makes New Investment in United Therapeutics Corporation $UTHR

Faithward Advisors LLC bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,269 shares of the biotechnology company’s stock, valued at approximately $3,542,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Clearstead Advisors LLC increased its position in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the period. Independent Advisor Alliance increased its position in United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Florida Financial Advisors LLC increased its position in United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares during the period. NDVR Inc. increased its position in United Therapeutics by 5.1% in the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after buying an additional 30 shares during the period. Finally, Principal Securities Inc. increased its position in United Therapeutics by 4.7% in the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock worth $334,000 after buying an additional 31 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 634,468 shares of company stock valued at $357,970,302 over the last ninety days. Corporate insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Royal Bank Of Canada decreased their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $549.57 on Tuesday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The stock has a market cap of $23.33 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 1.78 and a beta of 0.57. The business has a fifty day moving average of $566.45 and a 200-day moving average of $522.10.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the company posted $6.63 EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.